AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis' rival therapy Leqvio. Like Leqvio ...

The most common cholesterol-lowering drugs are statins, such as Lipitor and Crestor. These work by reducing the amount of ...

In one study, the drug reduced blood levels of free PCSK9 protein by more than 90% from baseline when administered to healthy men as a single dose of between 10 and 300 mg, regardless of the dose ...

Cholesterol is an important part of your body’s health, but too much of the wrong kind can lead to serious problems like ...

Drug discovery is the process through which potential ... We developed an epigenetic editor that targets PCSK9 and robustly and durably decreases LDL-C. The field of biogerontology has established ...

Evolucumab (Repatha) and alirocumab (Praluent) are injectable monoclonal antibodies. They have been joined by inclisiran ...

NewAmsterdam Pharma's obicetrapib lowers LDL-C in Phase 3 trials, showing promise as a CETP inhibitor. Read more on NAMS ...

LIB Therapeutics announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...